TISIDB

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Note=Colocalizes with CREBBP, EP300 and POLD1 to sites of DNA damage (PubMed:24939902). Forms nuclear foci representing sites of ongoing DNA replication and vary in morphology and number during S phase. Together with APEX2, is redistributed in discrete nuclear foci in presence of oxidative DNA damaging agents.
Domain	PF02747 Proliferating cell nuclear antigen PF00705 Proliferating cell nuclear antigen
Function	Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded onto DNA in order to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being conveniently positioned at the replication fork to coordinate DNA replication with DNA repair and DNA damage tolerance pathways (PubMed:24939902). Acts as a loading platform to recruit DDR proteins that allow completion of DNA replication after DNA damage and promote postreplication repair: Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination mechanisms to synthesize across the lesion.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000082 G1/S transition of mitotic cell cycle GO:0000083 regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0000302 response to reactive oxygen species GO:0000722 telomere maintenance via recombination GO:0000723 telomere maintenance GO:0000731 DNA synthesis involved in DNA repair GO:0001889 liver development GO:0006260 DNA replication GO:0006261 DNA-dependent DNA replication GO:0006271 DNA strand elongation involved in DNA replication GO:0006272 leading strand elongation GO:0006275 regulation of DNA replication GO:0006282 regulation of DNA repair GO:0006283 transcription-coupled nucleotide-excision repair GO:0006289 nucleotide-excision repair GO:0006296 nucleotide-excision repair, DNA incision, 5'-to lesion GO:0006297 nucleotide-excision repair, DNA gap filling GO:0006298 mismatch repair GO:0006301 postreplication repair GO:0006310 DNA recombination GO:0006312 mitotic recombination GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006979 response to oxidative stress GO:0007050 cell cycle arrest GO:0007093 mitotic cell cycle checkpoint GO:0007346 regulation of mitotic cell cycle GO:0007507 heart development GO:0009314 response to radiation GO:0009411 response to UV GO:0009416 response to light stimulus GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010948 negative regulation of cell cycle process GO:0016925 protein sumoylation GO:0018205 peptidyl-lysine modification GO:0019985 translesion synthesis GO:0022616 DNA strand elongation GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0031297 replication fork processing GO:0031570 DNA integrity checkpoint GO:0031571 mitotic G1 DNA damage checkpoint GO:0031960 response to corticosteroid GO:0032069 regulation of nuclease activity GO:0032070 regulation of deoxyribonuclease activity GO:0032075 positive regulation of nuclease activity GO:0032077 positive regulation of deoxyribonuclease activity GO:0032200 telomere organization GO:0032201 telomere maintenance via semi-conservative replication GO:0032355 response to estradiol GO:0033260 nuclear DNA replication GO:0033683 nucleotide-excision repair, DNA incision GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0034644 cellular response to UV GO:0042276 error-prone translesion synthesis GO:0042542 response to hydrogen peroxide GO:0042698 ovulation cycle GO:0042769 DNA damage response, detection of DNA damage GO:0042770 signal transduction in response to DNA damage GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044773 mitotic DNA damage checkpoint GO:0044774 mitotic DNA integrity checkpoint GO:0044783 G1 DNA damage checkpoint GO:0044786 cell cycle DNA replication GO:0044819 mitotic G1/S transition checkpoint GO:0044843 cell cycle G1/S phase transition GO:0044849 estrous cycle GO:0045005 DNA-dependent DNA replication maintenance of fidelity GO:0045739 positive regulation of DNA repair GO:0045740 positive regulation of DNA replication GO:0045786 negative regulation of cell cycle GO:0045787 positive regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0046686 response to cadmium ion GO:0048511 rhythmic process GO:0048545 response to steroid hormone GO:0048732 gland development GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051384 response to glucocorticoid GO:0060249 anatomical structure homeostasis GO:0061008 hepaticobiliary system development GO:0070301 cellular response to hydrogen peroxide GO:0070987 error-free translesion synthesis GO:0071156 regulation of cell cycle arrest GO:0071158 positive regulation of cell cycle arrest GO:0071214 cellular response to abiotic stimulus GO:0071478 cellular response to radiation GO:0071482 cellular response to light stimulus GO:0071548 response to dexamethasone GO:0071897 DNA biosynthetic process GO:0072331 signal transduction by p53 class mediator GO:0072395 signal transduction involved in cell cycle checkpoint GO:0072401 signal transduction involved in DNA integrity checkpoint GO:0072413 signal transduction involved in mitotic cell cycle checkpoint GO:0072422 signal transduction involved in DNA damage checkpoint GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint GO:0090068 positive regulation of cell cycle process GO:0090305 nucleic acid phosphodiester bond hydrolysis GO:0097421 liver regeneration GO:1901654 response to ketone GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902065 response to L-glutamate GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint GO:1902402 signal transduction involved in mitotic DNA damage checkpoint GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1902990 mitotic telomere maintenance via semi-conservative replication GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle GO:2001020 regulation of response to DNA damage stimulus GO:2001022 positive regulation of response to DNA damage stimulus
Molecular Function	GO:0000700 mismatch base pair DNA N-glycosylase activity GO:0000701 purine-specific mismatch base pair DNA N-glycosylase activity GO:0003682 chromatin binding GO:0003684 damaged DNA binding GO:0016798 hydrolase activity, acting on glycosyl bonds GO:0016799 hydrolase activity, hydrolyzing N-glycosyl compounds GO:0019104 DNA N-glycosylase activity GO:0030331 estrogen receptor binding GO:0030337 DNA polymerase processivity factor activity GO:0030971 receptor tyrosine kinase binding GO:0030983 mismatched DNA binding GO:0032135 DNA insertion or deletion binding GO:0032139 dinucleotide insertion or deletion binding GO:0032404 mismatch repair complex binding GO:0032405 MutLalpha complex binding GO:0035035 histone acetyltransferase binding GO:0035257 nuclear hormone receptor binding GO:0035258 steroid hormone receptor binding GO:0051427 hormone receptor binding GO:0070182 DNA polymerase binding GO:1990782 protein tyrosine kinase binding
Cellular Component	GO:0000781 chromosome, telomeric region GO:0000784 nuclear chromosome, telomeric region GO:0005657 replication fork GO:0005663 DNA replication factor C complex GO:0005813 centrosome GO:0030894 replisome GO:0032993 protein-DNA complex GO:0043596 nuclear replication fork GO:0043626 PCNA complex GO:0044454 nuclear chromosome part GO:0044796 DNA polymerase processivity factor complex GO:0070557 PCNA-p21 complex GO:0098687 chromosomal region

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03030 DNA replication hsa03410 Base excision repair hsa03420 Nucleotide excision repair hsa03430 Mismatch repair hsa04110 Cell cycle hsa04530 Tight junction
Reactome	R-HSA-73884: Base Excision Repair R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-73886: Chromosome Maintenance R-HSA-73893: DNA Damage Bypass R-HSA-5693532: DNA Double-Strand Break Repair R-HSA-73894: DNA Repair R-HSA-69306: DNA Replication R-HSA-69190: DNA strand elongation R-HSA-5696400: Dual Incision in GG-NER R-HSA-6782135: Dual incision in TC-NER R-HSA-113510: E2F mediated regulation of DNA replication R-HSA-180786: Extension of Telomeres R-HSA-1538133: G0 and Early G1 R-HSA-69206: G1/S Transition R-HSA-69205: G1/S-Specific Transcription R-HSA-5696397: Gap-filling DNA repair synthesis and ligation in GG-NER R-HSA-6782210: Gap-filling DNA repair synthesis and ligation in TC-NER R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER) R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA) R-HSA-5685942: HDR through Homologous Recombination (HRR) R-HSA-5693538: Homology Directed Repair R-HSA-69186: Lagging Strand Synthesis R-HSA-69109: Leading Strand Synthesis R-HSA-392499: Metabolism of proteins R-HSA-5358508: Mismatch Repair R-HSA-5358606: Mismatch repair (MMR) directed by MSH2 R-HSA-5358565: Mismatch repair (MMR) directed by MSH2 R-HSA-453279: Mitotic G1-G1/S phases R-HSA-5696398: Nucleotide Excision Repair R-HSA-5651801: PCNA-Dependent Long Patch Base Excision Repair R-HSA-69091: Polymerase switching R-HSA-174411: Polymerase switching on the C-strand of the telomere R-HSA-597592: Post-translational protein modification R-HSA-174414: Processive synthesis on the C-strand of the telomere R-HSA-69183: Processive synthesis on the lagging strand R-HSA-110314: Recognition of DNA damage by PCNA-containing replication complex R-HSA-69166: Removal of the Flap Intermediate R-HSA-174437: Removal of the Flap Intermediate from the C-strand R-HSA-110373: Resolution of AP sites via the multiple-nucleotide patch replacement pathway R-HSA-73933: Resolution of Abasic Sites (AP sites) R-HSA-69242: S Phase R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins R-HSA-2990846: SUMOylation R-HSA-4615885: SUMOylation of DNA replication proteins R-HSA-69239: Synthesis of DNA R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest R-HSA-174417: Telomere C-strand (Lagging Strand) Synthesis R-HSA-157579: Telomere Maintenance R-HSA-5656169: Termination of translesion DNA synthesis R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER) R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-110320: Translesion Synthesis by POLH R-HSA-5656121: Translesion synthesis by POLI R-HSA-5655862: Translesion synthesis by POLK R-HSA-110312: Translesion synthesis by REV1 R-HSA-110313: Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03030 DNA replication
hsa03410 Base excision repair
hsa03420 Nucleotide excision repair
hsa03430 Mismatch repair
hsa04110 Cell cycle
hsa04530 Tight junction

Reactome

R-HSA-73884: Base Excision Repair
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-73886: Chromosome Maintenance
R-HSA-73893: DNA Damage Bypass
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-69306: DNA Replication
R-HSA-69190: DNA strand elongation
R-HSA-5696400: Dual Incision in GG-NER
R-HSA-6782135: Dual incision in TC-NER
R-HSA-113510: E2F mediated regulation of DNA replication
R-HSA-180786: Extension of Telomeres
R-HSA-1538133: G0 and Early G1
R-HSA-69206: G1/S Transition
R-HSA-69205: G1/S-Specific Transcription
R-HSA-5696397: Gap-filling DNA repair synthesis and ligation in GG-NER
R-HSA-6782210: Gap-filling DNA repair synthesis and ligation in TC-NER
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5685942: HDR through Homologous Recombination (HRR)
R-HSA-5693538: Homology Directed Repair
R-HSA-69186: Lagging Strand Synthesis
R-HSA-69109: Leading Strand Synthesis
R-HSA-392499: Metabolism of proteins
R-HSA-5358508: Mismatch Repair
R-HSA-5358606: Mismatch repair (MMR) directed by MSH2
R-HSA-5358565: Mismatch repair (MMR) directed by MSH2
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-5651801: PCNA-Dependent Long Patch Base Excision Repair
R-HSA-69091: Polymerase switching
R-HSA-174411: Polymerase switching on the C-strand of the telomere
R-HSA-597592: Post-translational protein modification
R-HSA-174414: Processive synthesis on the C-strand of the telomere
R-HSA-69183: Processive synthesis on the lagging strand
R-HSA-110314: Recognition of DNA damage by PCNA-containing replication complex
R-HSA-69166: Removal of the Flap Intermediate
R-HSA-174437: Removal of the Flap Intermediate from the C-strand
R-HSA-110373: Resolution of AP sites via the multiple-nucleotide patch replacement pathway
R-HSA-73933: Resolution of Abasic Sites (AP sites)
R-HSA-69242: S Phase
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-4615885: SUMOylation of DNA replication proteins
R-HSA-69239: Synthesis of DNA
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
R-HSA-174417: Telomere C-strand (Lagging Strand) Synthesis
R-HSA-157579: Telomere Maintenance
R-HSA-5656169: Termination of translesion DNA synthesis
R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER)
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-110320: Translesion Synthesis by POLH
R-HSA-5656121: Translesion synthesis by POLI
R-HSA-5655862: Translesion synthesis by POLK
R-HSA-110312: Translesion synthesis by REV1
R-HSA-110313: Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PCNA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between PCNA and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
22021614	Pancreatic Ductal Adenocarcinoma; Prostate Carcinoma; Breast Adenocarcinoma; Glioblastoma; Melanoma; Cervical Adenocarcinoma	Inhibit immunity	Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. Proliferating cell nuclear Ag (PCNA) is overexpressed in cancer cells. Their interaction inhibits NK cell function through NKp44/ITIM. The physical interaction of NKp44 and PCNA is enabled by recruitment of target cell PCNA to the NK immunological synapse. We demonstrate that PCNA promotes cancer survival by immune evasion through inhibition of NKp44-mediated NK cell attack.
23312906	Glioma; Mesothelioma	Inhibit immunity	In two non epithelial cancers (glioma and mesothelioma), we found that the epigenetic regulation of the NY-ESO1 gene requires the sequential recruitment of the HDAC1-mSin3a-NCOR, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a complexes.The NY-ESO1 gene is a cancer/testis antigen considered to be suitable target for the immunotherapy of human malignancies.

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PCNA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PCNA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.002	0.994
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.076	0.979
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.069	0.976
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.606	0.299
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.165	0.912
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.592	0.455
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.149	0.722
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.414	0.826
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.181	0.93
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.161	0.934
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.314	0.918
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.381	0.00018

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PCNA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PCNA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PCNA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PCNA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PCNA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PCNA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PCNA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PCNA
Name	proliferating cell nuclear antigen
Aliases	ATLD2; DNA polymerase delta auxiliary protein; cyclin
Chromosomal Location	20p13-p12.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PCNA collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting PCNA.

ID	Name	Drug Type	Targets	#Targets
DB00279	Liothyronine	Small Molecule	PCNA, THRA, THRB	3

Browse PCNA